Drug Trial Radar · NCT01796002
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
421
Actual
Start
Jan 2013
Primary completion
Dec 13, 2019
Study completion Dec 13, 2022
Sponsor
- Lead sponsor
- The Lymphoma Academic Research OrganisationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).
Conditions
- Peripheral T-cell Lymphoma
Interventions
Romidepsin + CHOPDrug
Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
CHOPDrug
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint is Progression Free SurvivalTime frame: 60 months
Locations
131 sites in 8 countries. Site status is shown where the registry gives one.
ZNA Stuivenberg
Antwerp, Belgium
A.Z. Sint Jan AV
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
UCL Louvain Saint Luc
Brussels, Belgium
ULB - Hôpital Erasme
Brussels, Belgium
Grand Hôpital de Charleroi
Charleroi, Belgium
Hôpital Jolimont
Haine-Saint-Paul, Belgium
AZ VUB
Jette, Belgium
AZ Groeninge
Kortrijk, Belgium
CHC - Clinique Saint Joseph
Liège, Belgium
CHU de Liege
Liège, Belgium
CHU Mont Godinne
Yvoir, Belgium
CHU d'Amiens
Amiens, France
CHU d'Angers
Angers, France
CH de Annecy
Annecy, France
CH Henri Duffaut
Avignon, France
CH Côte Basque
Bayonne, France
CHU Jean Minjoz
Besançon, France
CH de Béziers
Béziers, France
CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie
Bordeaux, France
Institut Bergonié
Bordeaux, France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France
CH du Dr Duchenne
Boulogne-sur-Mer, France
CH de Bourg en Bresse
Bourg-en-Bresse, France
Centre François Baclesse
Caen, France
Institut d'Hématologie de Basse-Normandie
Caen, France
CH de Chalon sur Saône
Chalon-sur-Saône, France
CH de Chambéry
Chambéry, France
Hôpital Antoine Béclère
Clamart, France
CHU Estaing
Clermont-Ferrand, France
Hôpital Pasteur
Colmar, France
CH Sud Francilien de Corbeil
Corbeil-Essonnes, France
CHU Henri Mondor
Créteil, France
CHU de Dijon
Dijon, France
CH de Dunkerque
Dunkirk, France
CHU de Grenoble
Grenoble, France
CHD La Roche sur Yon
La Roche-sur-Yon, France
Centre Hospitalier de Versailles - André Mignot
Le Chesnay, France
Hôpital Kremlin Bicêtre
Le Kremlin-Bicêtre, France
CH du Mans
Le Mans, France
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.